Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma
A method for simultaneous bioanalysis of the three cytotoxic drugs cytosine arabinoside, daunorubicin and etoposide in human plasma was developed and validated. A HPLC method with ultra-violet and fluorescence detection, preceded by mixed-mode cation-exchange solid phase extraction sample preparatio...
Gespeichert in:
| Veröffentlicht in: | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2010-07, Vol.878 (22), p.1967-1972 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1972 |
|---|---|
| container_issue | 22 |
| container_start_page | 1967 |
| container_title | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences |
| container_volume | 878 |
| creator | Krogh-Madsen, Mikkel Hansen, Steen Honoré Honoré, Per Hartvig |
| description | A method for simultaneous bioanalysis of the three cytotoxic drugs cytosine arabinoside, daunorubicin and etoposide in human plasma was developed and validated. A HPLC method with ultra-violet and fluorescence detection, preceded by mixed-mode cation-exchange solid phase extraction sample preparation, was used for the quantification of the analytes. The assay was used for the simultaneous measurement of cytosine arabinoside, daunorubicin and etoposide with linearity in the ranges of 13–1500
ng/mL, 15–1000
ng/mL and 52.5–3500
ng/mL, respectively. The chromatographic run-time was 15.5
min. The overall precision (% relative standard deviation) was within 0.2–13.5% and the recovery ranged between 86.1% and 110.1% for the three drugs at all concentrations tested. Plasma samples were stable for at least two months when stored at −20
°C. The method was successfully applied to quantification of the three drugs in blood samples from patients undergoing induction treatment for acute myeloid leukaemia, thus demonstrating its suitability for clinical studies. |
| doi_str_mv | 10.1016/j.jchromb.2010.05.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_753688394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570023210003521</els_id><sourcerecordid>753688394</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-56c46eee403e64757988605fce6fb6e6d81ea11b5e011839a45ea7fd658f40503</originalsourceid><addsrcrecordid>eNqFkU2PFCEQhonRuB_6EzRcjJftsWga6DmZzcavZBMPauJJUg3VWSbdMEK3yf57GWfU456oFM9LvdTL2AsBGwFCv9ltdu4up3nYtFB7oDYgxSN2LnojG2n098e1VgYaaGV7xi5K2QEIA0Y-ZWctqK7tjDpnP76EeZ0WjJTWwj0tlOcQcQkp8jRyd7-kEiJxzDiEWGtPV9zjGlNeh-BC5Bg9pyXt_9zx2rhbZ4x8P2GZ8Rl7MuJU6PnpvGTf3r_7evOxuf384dPN9W3jVCuWRmnXaSLqQJKuvsy27zWo0ZEeB03a94JQiEERCNHLLXaK0Ixeq37sQIG8ZK-P7-5z-rlSWewciqNpOn7MGiV1X4Xdw6SUumuF0JVUR9LlVEqm0e5zmDHfWwH2kIHd2VMG9pCBBWVrBlX38jRhHWby_1R_l16BVycAi8NpzBhdKP-5drsFgIPVt0eO6uZ-Bcq2uEDRkQ-Z3GJ9Cg9Y-Q2Gz6hU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733642116</pqid></control><display><type>article</type><title>Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Krogh-Madsen, Mikkel ; Hansen, Steen Honoré ; Honoré, Per Hartvig</creator><creatorcontrib>Krogh-Madsen, Mikkel ; Hansen, Steen Honoré ; Honoré, Per Hartvig</creatorcontrib><description>A method for simultaneous bioanalysis of the three cytotoxic drugs cytosine arabinoside, daunorubicin and etoposide in human plasma was developed and validated. A HPLC method with ultra-violet and fluorescence detection, preceded by mixed-mode cation-exchange solid phase extraction sample preparation, was used for the quantification of the analytes. The assay was used for the simultaneous measurement of cytosine arabinoside, daunorubicin and etoposide with linearity in the ranges of 13–1500
ng/mL, 15–1000
ng/mL and 52.5–3500
ng/mL, respectively. The chromatographic run-time was 15.5
min. The overall precision (% relative standard deviation) was within 0.2–13.5% and the recovery ranged between 86.1% and 110.1% for the three drugs at all concentrations tested. Plasma samples were stable for at least two months when stored at −20
°C. The method was successfully applied to quantification of the three drugs in blood samples from patients undergoing induction treatment for acute myeloid leukaemia, thus demonstrating its suitability for clinical studies.</description><identifier>ISSN: 1570-0232</identifier><identifier>EISSN: 1873-376X</identifier><identifier>DOI: 10.1016/j.jchromb.2010.05.031</identifier><identifier>PMID: 20542475</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>AML ; Analysis ; Analytical, structural and metabolic biochemistry ; Biological and medical sciences ; Blood ; Chromatography ; Chromatography, High Pressure Liquid - methods ; Cytarabine - blood ; Cytosine arabinoside ; Daunorubicin ; Daunorubicin - blood ; Drugs ; Etoposide ; Etoposide - blood ; Fluorescence ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; HPLC ; Human ; Humans ; Leukaemia ; Medical sciences ; Pharmacology. Drug treatments ; Plasma ; Solid phases ; Standard deviation</subject><ispartof>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010-07, Vol.878 (22), p.1967-1972</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-56c46eee403e64757988605fce6fb6e6d81ea11b5e011839a45ea7fd658f40503</citedby><cites>FETCH-LOGICAL-c521t-56c46eee403e64757988605fce6fb6e6d81ea11b5e011839a45ea7fd658f40503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jchromb.2010.05.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22990004$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20542475$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krogh-Madsen, Mikkel</creatorcontrib><creatorcontrib>Hansen, Steen Honoré</creatorcontrib><creatorcontrib>Honoré, Per Hartvig</creatorcontrib><title>Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma</title><title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</title><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><description>A method for simultaneous bioanalysis of the three cytotoxic drugs cytosine arabinoside, daunorubicin and etoposide in human plasma was developed and validated. A HPLC method with ultra-violet and fluorescence detection, preceded by mixed-mode cation-exchange solid phase extraction sample preparation, was used for the quantification of the analytes. The assay was used for the simultaneous measurement of cytosine arabinoside, daunorubicin and etoposide with linearity in the ranges of 13–1500
ng/mL, 15–1000
ng/mL and 52.5–3500
ng/mL, respectively. The chromatographic run-time was 15.5
min. The overall precision (% relative standard deviation) was within 0.2–13.5% and the recovery ranged between 86.1% and 110.1% for the three drugs at all concentrations tested. Plasma samples were stable for at least two months when stored at −20
°C. The method was successfully applied to quantification of the three drugs in blood samples from patients undergoing induction treatment for acute myeloid leukaemia, thus demonstrating its suitability for clinical studies.</description><subject>AML</subject><subject>Analysis</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Chromatography</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Cytarabine - blood</subject><subject>Cytosine arabinoside</subject><subject>Daunorubicin</subject><subject>Daunorubicin - blood</subject><subject>Drugs</subject><subject>Etoposide</subject><subject>Etoposide - blood</subject><subject>Fluorescence</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General pharmacology</subject><subject>HPLC</subject><subject>Human</subject><subject>Humans</subject><subject>Leukaemia</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasma</subject><subject>Solid phases</subject><subject>Standard deviation</subject><issn>1570-0232</issn><issn>1873-376X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2PFCEQhonRuB_6EzRcjJftsWga6DmZzcavZBMPauJJUg3VWSbdMEK3yf57GWfU456oFM9LvdTL2AsBGwFCv9ltdu4up3nYtFB7oDYgxSN2LnojG2n098e1VgYaaGV7xi5K2QEIA0Y-ZWctqK7tjDpnP76EeZ0WjJTWwj0tlOcQcQkp8jRyd7-kEiJxzDiEWGtPV9zjGlNeh-BC5Bg9pyXt_9zx2rhbZ4x8P2GZ8Rl7MuJU6PnpvGTf3r_7evOxuf384dPN9W3jVCuWRmnXaSLqQJKuvsy27zWo0ZEeB03a94JQiEERCNHLLXaK0Ixeq37sQIG8ZK-P7-5z-rlSWewciqNpOn7MGiV1X4Xdw6SUumuF0JVUR9LlVEqm0e5zmDHfWwH2kIHd2VMG9pCBBWVrBlX38jRhHWby_1R_l16BVycAi8NpzBhdKP-5drsFgIPVt0eO6uZ-Bcq2uEDRkQ-Z3GJ9Cg9Y-Q2Gz6hU</recordid><startdate>20100715</startdate><enddate>20100715</enddate><creator>Krogh-Madsen, Mikkel</creator><creator>Hansen, Steen Honoré</creator><creator>Honoré, Per Hartvig</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TB</scope><scope>8FD</scope><scope>FR3</scope></search><sort><creationdate>20100715</creationdate><title>Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma</title><author>Krogh-Madsen, Mikkel ; Hansen, Steen Honoré ; Honoré, Per Hartvig</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-56c46eee403e64757988605fce6fb6e6d81ea11b5e011839a45ea7fd658f40503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>AML</topic><topic>Analysis</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Chromatography</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Cytarabine - blood</topic><topic>Cytosine arabinoside</topic><topic>Daunorubicin</topic><topic>Daunorubicin - blood</topic><topic>Drugs</topic><topic>Etoposide</topic><topic>Etoposide - blood</topic><topic>Fluorescence</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General pharmacology</topic><topic>HPLC</topic><topic>Human</topic><topic>Humans</topic><topic>Leukaemia</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasma</topic><topic>Solid phases</topic><topic>Standard deviation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krogh-Madsen, Mikkel</creatorcontrib><creatorcontrib>Hansen, Steen Honoré</creatorcontrib><creatorcontrib>Honoré, Per Hartvig</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krogh-Madsen, Mikkel</au><au>Hansen, Steen Honoré</au><au>Honoré, Per Hartvig</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma</atitle><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><date>2010-07-15</date><risdate>2010</risdate><volume>878</volume><issue>22</issue><spage>1967</spage><epage>1972</epage><pages>1967-1972</pages><issn>1570-0232</issn><eissn>1873-376X</eissn><abstract>A method for simultaneous bioanalysis of the three cytotoxic drugs cytosine arabinoside, daunorubicin and etoposide in human plasma was developed and validated. A HPLC method with ultra-violet and fluorescence detection, preceded by mixed-mode cation-exchange solid phase extraction sample preparation, was used for the quantification of the analytes. The assay was used for the simultaneous measurement of cytosine arabinoside, daunorubicin and etoposide with linearity in the ranges of 13–1500
ng/mL, 15–1000
ng/mL and 52.5–3500
ng/mL, respectively. The chromatographic run-time was 15.5
min. The overall precision (% relative standard deviation) was within 0.2–13.5% and the recovery ranged between 86.1% and 110.1% for the three drugs at all concentrations tested. Plasma samples were stable for at least two months when stored at −20
°C. The method was successfully applied to quantification of the three drugs in blood samples from patients undergoing induction treatment for acute myeloid leukaemia, thus demonstrating its suitability for clinical studies.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>20542475</pmid><doi>10.1016/j.jchromb.2010.05.031</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1570-0232 |
| ispartof | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010-07, Vol.878 (22), p.1967-1972 |
| issn | 1570-0232 1873-376X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_753688394 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | AML Analysis Analytical, structural and metabolic biochemistry Biological and medical sciences Blood Chromatography Chromatography, High Pressure Liquid - methods Cytarabine - blood Cytosine arabinoside Daunorubicin Daunorubicin - blood Drugs Etoposide Etoposide - blood Fluorescence Fundamental and applied biological sciences. Psychology General pharmacology HPLC Human Humans Leukaemia Medical sciences Pharmacology. Drug treatments Plasma Solid phases Standard deviation |
| title | Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A54%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simultaneous%20determination%20of%20cytosine%20arabinoside,%20daunorubicin%20and%20etoposide%20in%20human%20plasma&rft.jtitle=Journal%20of%20chromatography.%20B,%20Analytical%20technologies%20in%20the%20biomedical%20and%20life%20sciences&rft.au=Krogh-Madsen,%20Mikkel&rft.date=2010-07-15&rft.volume=878&rft.issue=22&rft.spage=1967&rft.epage=1972&rft.pages=1967-1972&rft.issn=1570-0232&rft.eissn=1873-376X&rft_id=info:doi/10.1016/j.jchromb.2010.05.031&rft_dat=%3Cproquest_cross%3E753688394%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733642116&rft_id=info:pmid/20542475&rft_els_id=S1570023210003521&rfr_iscdi=true |